EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Multigene Signature for Prognostic Stratification of Nasopharyngeal Carcinoma

Yingying Liang iD, Zhiwen Mo, Muy-Teck Teh iD

Cancers · 09.04.2026 · 18 (8) · 1197

DOI: 10.3390/cancers18081197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 09.04.2026. Verfasst von Yingying Liang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Plan on enhancing scientific research in Guangzhou Medical University, Barts Charity, Plan on Enhancing Scientific Research in GMU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously pioneered a multigene mRNA test, qMIDSV2, validated through an international multicohort study with geographically and ethnically diverse oral squamous cell carcinoma (OSCC) patients from Europe and Asia. This study aimed to repurpose the qMIDSV2 test for nasopharyngeal carcinoma (NPC). A molecular test independent of Epstein–Barr virus (EBV) status would be clinically useful for risk stratification in NPC patients with undetectable or low levels of EBV.

Methods

This study investigated a Chinese cohort of 62 participants (18 donated normal nasopharyngeal mucosa (NPM) and 44 donated NPC tissue samples). Messenger RNA levels of 16 genes in each sample were quantified using the qPCR method, and an algorithm computed a malignancy index for cancer risk stratification.

Results

We identified a unique 10-gene panel (containing eight target genes, namely NEK2, INHBA, FOXM1, TOP2A, BIRC5, CXCL8, NR3C1, and IVL, relative to two reference genes, YAP1 and POLR2A, collectively named qMIDSNPC) that demonstrated the best overall diagnostic performance in segregating NPM from NPC, with AUC = 0.909 and positive/negative predictive values of 91% PPV and 78% NPV, respectively. Furthermore, we demonstrated prognostic value of qMIDSNPC in segregating NPM from NPC stage III + IV, with AUC = 0.936, 92% PPV, and 84% NPV.

Conclusions

Here, we present a simple qPCR-based 10-gene mRNA test, qMIDSNPC, with potential clinical utilities for rapid (1 h) prognostic stratification of NPC. Further studies involving geographically and ethnically independent NPC cohorts would be needed to validate the clinical use of qMIDSNPC in non-endemic NPC populations.

Schlagwörter

Stichwörter der Autor:innen

Epstein–Barr virus (EBV)-independent detectionmRNA biomarkersmolecular diagnosticsnasopharyngeal carcinomaqMIDSrisk stratificationsquamous cell carcinoma

Autor:innen und Institutionen

  • Department of Radiation Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou 510095, China.
  • Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.

ORCID-Profile: Yingying Liang, Muy-Teck Teh

Förderung

  • Plan on enhancing scientific research in Guangzhou Medical University
  • Barts Charity
  • Plan on Enhancing Scientific Research in GMU

Zitieren

APA

Liang, Y., Mo, Z., & Teh, M. T. (2026). A Multigene Signature for Prognostic Stratification of Nasopharyngeal Carcinoma. Cancers, 18(8), 1197. https://doi.org/10.3390/cancers18081197

Vancouver

Liang Y, Mo Z, Teh MT. A Multigene Signature for Prognostic Stratification of Nasopharyngeal Carcinoma. Cancers. 2026;18(8):1197. doi:10.3390/cancers18081197

BibTeX
@article{Liang2026,
  author = {Liang, Yingying and Mo, Zhiwen and Teh, Muy-Teck},
  title = {A Multigene Signature for Prognostic Stratification of Nasopharyngeal Carcinoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1197},
  doi = {10.3390/cancers18081197}
}
Kostenlos starten →